BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

CE Celebration

The Pyrexar team is celebrating their new ISO 13485 Certification and CE re-certification today. ISO 13485 represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.  The ISO standard is also a required compliance to do business in the European Union. The CE mark,  a mandatory conformity marking for products sold within the European Economic Area (EEA) since 1985, allows Pyrexar to ship medical devices to any of the 27 Member States of the EU.  Much like the FDA clearance in the U.S., the CE mark is well respected and plays a key role in acceptance with regulatory agencies of other nations.

We are proud to announce two new additions to the ICHO/Pyrexar Day event calendar.

Curt HeeseDr. Curt Heese, board-certified radiation oncologist at Cancer Treatment Centers of America, Philadelphia. Dr. Heese will be sharing his experiences using Pyrexar Hyperthermia systems as an adjunct therapy to treat pancreatic cancer.

 

 

Niloy DattaDr. Niloy Datta, oncologist and prolific researcher in the field of hyperthermia at Kantonspital Aarau AG, Aarau, Switzerland.  Dr. Niloy Data will be sharing early results from a multi-institutional phase I/II clinical study "Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (HYPROSAR).

Our goal is to make hyperthermia the "standard of care" in the treatment of cancer.  Please join us in spreading the word.

 

pyrexar day

west indiesPlease welcome our new distribution partner,  Clinitech Company Ltd,  bringing the hyperthermia technologies into Cuba, the West Indies, Panama, and Venezuela.

Cancer deaths are high (138 per 100,000) in Cuba, according to World Life Expectancy.com, an organization that tracks death causality throughout the world.  Cuba's cancer stats rank 31 in the world, slightly lower than the UK, and several points higher than the USA.   According to a study in 2001-2003 by the National Cancer Registry, Lung, Prostate, Throat, and Colon had a high incidence in men, while Breast, Cervix, Lung, and Colon cancers were the most prevalent in women.

clinitech logo v2

Clinitech will be providing sales and service for the Pyrexar family of Superficial, Interstitial, and Deep Regional Hyperthermia devices. Leading their team is Ross University School of Medicine, Oncology Professor, Dr. Kamal Malaker, who has successfully used Hyperthermia technology in the treatment of cancer. “We are excited to bring this relatively under-explored, underutilized, well-proven, life-saving technology to the region,” says Wazir Mohammed, Clinitech’s President.

The distribution territory includes Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Montserrat, Panama, Puerto Rico, Saba, St. Ecstasies. St Kitts & Nevis, St Lucia, St Maarten, St Vincent. Suriname, Trinidad, and Tobago. Turks and Caicos. US Virgin Islands (St. Thomas, St. Croix, St John), Venezuela. Visit the "How to Buy" page for contact information.

"Pyrexar must continue our expansion to ensure our cancer-fighting system is offered worldwide, to all cancer patients" - Mark Falkowski, CEO.

new building introJust under a year ago, Pyrexar purchased the hyperthermia device group from Perseon Medical (formerly BSD Medical).  As part of the original purchase agreement, Perseon acquired 19.9% of our company, along with royalties on future sales of the BSD-2000, our flagship product. Fees alone were estimated at $4 million over the next three years.

Today, we purchased that ownership back! 

Pyrexar is whole again and continuing to grow and move forward.  Every single department in the company has made incredible strides in efficiency, productivity, and expansion.  The details may not be an exciting read, but they go along way to make Pyrexar a very successful business case study.

Here are some highlights!

New Distribution - Added nine new international distribution companies to our channel with several more in negotiation bringing our sales coverage to 31 countries

Revamped Manufacturing Workflow - We increased the speed of our manufacturing process by 600%.

Regulatory Process - Added TFDA (Taiwan FDA), KFDA (Korean FDA), TUV Rheinland, and RoHs compliance to our process.

Engineering Updates - Manufacturing processes are being re-engineered to be more efficient and cost-effective. Plus, we are well into a product road-map of new and exciting thermal therapy products

These improvements, along with a laundry list of incremental achievements, make the company more organized, cost-efficient, proactive, and flexible.

Thank you for helping us continue the work that brings life-saving hyperthermia to cancer patients around the world.